Updates from the EURO-SKI trial of tyrosine kinase cessation
3 Dec 2016
Updates from the EURO-SKI trial of tyrosine kinase cessation
CML patients with stable response may safely decrease dose of TKI
Novel antibody boosts responses in newly diagnosed AML
Vadastuximab talirine in combination for newly diagnosed AML
Subgroup analysis of elderly high risk AML patients receiving CPX-351
A new spin on leukaemia therapy
Cancer care in Kazakhstan
Advanced oral cancer in St Petersburg
Treatment of primary thyroid cancers
Editor's Choice for November 2016
Mindful management of microcarcinomas
Radiotherapy or surgery for oral cavity tumours?